Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Parkinson's Disease

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 175 articles:
HTML format
Text format



Single Articles


    March 2017
  1. PAKPOOR J, Noyce A, Goldacre R, Selkihova M, et al
    Viral hepatitis and Parkinson disease: A national record-linkage study.
    Neurology. 2017 Mar 29. pii: 10.1212/WNL.0000000000003848.
    PubMed     Text format     Abstract available


  2. BENITO-LEON J
    Viral hepatitis and the risk of Parkinson disease.
    Neurology. 2017 Mar 29. pii: 10.1212/WNL.0000000000003853.
    PubMed     Text format    


  3. ROCHESTER L, Galna B, Lord S, Yarnall AJ, et al
    Decrease in Abeta42 predicts dopa-resistant gait progression in early Parkinson disease.
    Neurology. 2017 Mar 22. pii: 10.1212/WNL.0000000000003840.
    PubMed     Text format     Abstract available


  4. NONNEKES J, Janssen S, Bloem BR
    Superficial brain stimulation to overcome freezing of gait in Parkinson disease.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003859.
    PubMed     Text format    


  5. SAARI L, Kivinen K, Gardberg M, Joutsa J, et al
    Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003810.
    PubMed     Text format     Abstract available


    February 2017
  6. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    


  7. BOHNEN NI, Muller M
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:920.
    PubMed     Text format    


  8. BUCHMAN AS, Bennett DA
    Author response: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919-920.
    PubMed     Text format    


  9. MAHLKNECHT P, Kiechl S, Willeit J, Poewe W, et al
    Letter re: Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2017;88:919.
    PubMed     Text format    


  10. GOLDMAN JG, Bledsoe IO, Merkitch D, Dinh V, et al
    Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003764.
    PubMed     Text format     Abstract available


  11. MERY VP, Gros P, Lafontaine AL, Robinson A, et al
    Reduced cognitive function in patients with Parkinson disease and obstructive sleep apnea.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003738.
    PubMed     Text format     Abstract available


  12. LEWITT PA, Li J, Lu M, Guo L, et al
    Metabolomic biomarkers as strong correlates of Parkinson disease progression.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003663.
    PubMed     Text format     Abstract available


  13. ALVES G, Bonanni L
    Neurofilament light: A heavyweight diagnostic biomarker in neurodegenerative parkinsonism?
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003699.
    PubMed     Text format    


  14. HANSSON O, Janelidze S, Hall S, Magdalinou N, et al
    Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003680.
    PubMed     Text format     Abstract available


    January 2017
  15. EWENCZYK C, Mesmoudi S, Gallea C, Welter ML, et al
    Antisaccades in Parkinson disease: A new marker of postural control?
    Neurology. 2017 Jan 27. pii: 10.1212/WNL.0000000000003658.
    PubMed     Text format     Abstract available


  16. PEDERSEN KF, Larsen JP, Tysnes OB, Alves G, et al
    Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.
    Neurology. 2017 Jan 20. pii: 10.1212/WNL.0000000000003634.
    PubMed     Text format     Abstract available


  17. FEDOROVA TD, Seidelin LB, Knudsen K, Schacht AC, et al
    Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study.
    Neurology. 2017 Jan 18. pii: 10.1212/WNL.0000000000003633.
    PubMed     Text format     Abstract available


    December 2016
  18. RACETTE BA, Searles Nielsen S, Criswell SR, Sheppard L, et al
    Dose-dependent progression of parkinsonism in manganese-exposed welders.
    Neurology. 2016 Dec 28. pii: 10.1212/WNL.0000000000003533.
    PubMed     Text format     Abstract available


  19. RATNER MH, Fitzgerald E
    Understanding of the role of manganese in parkinsonism and Parkinson disease.
    Neurology. 2016 Dec 28. pii: 10.1212/WNL.0000000000003543.
    PubMed     Text format    


  20. THOLFSEN LK, Larsen JP, Schulz J, Tysnes OB, et al
    Changes in insomnia subtypes in early Parkinson disease.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003540.
    PubMed     Text format     Abstract available


    November 2016
  21. CENTI J, Freeman R, Gibbons CH, Neargarder S, et al
    Effects of orthostatic hypotension on cognition in Parkinson disease.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003452.
    PubMed     Text format     Abstract available


  22. BOYLAN LS, Messinis L
    Orthostatic hypotension, cognition, and Parkinson disease: Dumbing down by standing up.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003468.
    PubMed     Text format    


  23. MANO T, Britton Z, Britton T
    Anatomo-functional basis of nonmotor symptoms in Parkinson disease.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003443.
    PubMed     Text format    


  24. PYATIGORSKAYA N, Mongin M, Valabregue R, Yahia-Cherif L, et al
    Medulla oblongata damage and cardiac autonomic dysfunction in Parkinson disease.
    Neurology. 2016 Nov 11. pii: 10.1212/WNL.0000000000003426.
    PubMed     Text format     Abstract available


  25. PAGANO G, Molloy S, Bain PG, Rabiner EA, et al
    Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003396.
    PubMed     Text format     Abstract available


    October 2016
  26. MATTIS PJ, Niethammer M, Sako W, Tang CC, et al
    Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003285.
    PubMed     Text format     Abstract available


  27. BRYS M, Fox MD, Agarwal S, Biagioni M, et al
    Multifocal repetitive TMS for motor and mood symptoms of Parkinson disease: A randomized trial.
    Neurology. 2016 Oct 5. pii: 10.1212/WNL.0000000000003279.
    PubMed     Text format     Abstract available


    September 2016
  28. UMEMOTO G, Fujioka S, Yanamoto S, Fukae J, et al
    A case of sudden deterioration in Parkinson disease.
    Neurology. 2016;87:1422.
    PubMed     Text format    


  29. MORGANTE F, Fasano A, Ginevrino M, Petrucci S, et al
    Impulsive-compulsive behaviors in parkin-associated Parkinson disease.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003177.
    PubMed     Text format     Abstract available


  30. BJORNESTAD A, Tysnes OB, Larsen JP, Alves G, et al
    Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003213.
    PubMed     Text format     Abstract available


    August 2016
  31. QUATTRONE A, Morelli M, Williams DR, Vescio B, et al
    MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism.
    Neurology. 2016 Aug 24. pii: 10.1212/WNL.0000000000003125.
    PubMed     Text format     Abstract available


  32. BARICHELLA M, Pacchetti C, Bolliri C, Cassani E, et al
    Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT.
    Neurology. 2016 Aug 19. pii: 10.1212/WNL.0000000000003127.
    PubMed     Text format     Abstract available


  33. SIDIROPOULOS C, LeWitt PA, Odekerken VJ, Schuurman PR, et al
    GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.
    Neurology. 2016;87:745-6.
    PubMed     Text format    


  34. BUCHMAN AS, Leurgans SE, Yu L, Wilson RS, et al
    Incident parkinsonism in older adults without Parkinson disease.
    Neurology. 2016 Aug 3. pii: 10.1212/WNL.0000000000003059.
    PubMed     Text format     Abstract available


    July 2016
  35. BOYD JT, Wangensteen KJ, Krawitt EL, Hamill RW, et al
    Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study.
    Neurology. 2016;87:342.
    PubMed     Text format    


  36. BURCIU RG, Chung JW, Shukla P, Ofori E, et al
    Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002985.
    PubMed     Text format     Abstract available



  37. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
    Neurology. 2016;87:239.
    PubMed     Text format    


  38. JELLINGER KA, Logroscino G, Rizzo G, Copetti M, et al
    Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016;87:237-8.
    PubMed     Text format    


  39. GIBBONS CH, Garcia J, Wang N, Shih LC, et al
    The diagnostic discrimination of cutaneous alpha-synuclein deposition in Parkinson disease.
    Neurology. 2016 Jul 6. pii: 10.1212/WNL.0000000000002919.
    PubMed     Text format     Abstract available


    June 2016
  40. GOODARZI Z, Mrklas KJ, Roberts DJ, Jette N, et al
    Detecting depression in Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002898.
    PubMed     Text format     Abstract available


  41. COLLOBY SJ, McKeith IG, Burn DJ, Wyper DJ, et al
    Cholinergic and perfusion brain networks in Parkinson disease dementia.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002839.
    PubMed     Text format     Abstract available


    May 2016
  42. OSAKI Y, Fujita K, Abe T, Harada M, et al
    Mystery Case: Parkinsonism in a diabetic uremic patient.
    Neurology. 2016;86:e225-7.
    PubMed     Text format    


  43. VAN DER HEEDEN JF, Marinus J, Martinez-Martin P, Rodriguez-Blazquez C, et al
    Postural instability and gait are associated with severity and prognosis of Parkinson disease.
    Neurology. 2016 May 13. pii: 10.1212/WNL.0000000000002768.
    PubMed     Text format     Abstract available


  44. FACTOR SA, Bennett A, Hohler AD, Wang D, et al
    Quality improvement in neurology: Parkinson disease update quality measurement set: Executive summary.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002670.
    PubMed     Text format    


  45. CHAUDHURI KR
    Progression and biomarkers for Parkinson disease: Merging motor with nonmotor symptoms.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002664.
    PubMed     Text format    


  46. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Monitoring of 30 marker candidates in early Parkinson disease as progression markers.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002651.
    PubMed     Text format     Abstract available


  47. LATTANZI S, Silvestrini M, Verbeek MM, Mollenhauer B, et al
    Increased CSF biomarkers of angiogenesis in Parkinson disease.
    Neurology. 2016;86:1747-8.
    PubMed     Text format    


    April 2016
  48. BOHNEN NI, Muller ML, Sohn YH, Lee DH, et al
    Is normosmic Parkinson disease a unique clinical phenotype?
    Neurology. 2016;86:1649-50.
    PubMed     Text format    


  49. MASSANO J, Bronstein JM
    Writeclick: Neuropsychological outcome after deep brain stimulation for Parkinson disease.
    Neurology. 2016;86:1563-4.
    PubMed     Text format    


  50. LOVERA LC, Rodriguez-Porcel F, Urrea-Mendoza E, Fasano A, et al
    Flamenco dancer posture: Unique "off" complication in Parkinson disease.
    Neurology. 2016;86:1462-3.
    PubMed     Text format    


  51. LEWITT PA, Fahn S
    Levodopa therapy for Parkinson disease: A look backward and forward.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  52. SILVER DE, Trosch RM
    Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  53. DHALL R, Kreitzman DL
    Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
    Neurology. 2016;86.
    PubMed     Text format     Abstract available


  54. GUPTA S
    Advances in levodopa therapy for Parkinson disease.
    Neurology. 2016;86.
    PubMed     Text format    


    March 2016
  55. ABE K, Bohnen NI, Muller ML, van der Holst HM, et al
    Cerebral small vessel disease and incident parkinsonism: The RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    


  56. BOHNEN NI, Muller ML
    Cerebral small vessel disease and incident parkinsonism: the RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    


  57. ABE K
    Cerebral small vessel disease and incident parkinsonism: the RUN DMC study.
    Neurology. 2016;86:1268-9.
    PubMed     Text format    



  58. Hepcidin ameliorates mitochondrial damage in a rat model of Parkinson's disease (P3.019).
    Neurology. 2016;86:1077.
    PubMed     Text format    


  59. SCHERFLER C, Gobel G, Muller C, Nocker M, et al
    Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism.
    Neurology. 2016 Mar 2. pii: 10.1212/WNL.0000000000002518.
    PubMed     Text format     Abstract available


    February 2016
  60. ROUSSAKIS AA, Politis M, Towey D, Piccini P, et al
    Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
    Neurology. 2016 Feb 26. pii: 10.1212/WNL.0000000000002494.
    PubMed     Text format     Abstract available


  61. VELSEBOER DC, de Bie RM, Wieske L, Evans JR, et al
    Development and external validation of a prognostic model in newly diagnosed Parkinson disease.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002437.
    PubMed     Text format     Abstract available


  62. CHIO A, Defazio G
    A new scale for prognostication in Parkinson disease: Of animals and men.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002435.
    PubMed     Text format    


  63. STERLING NW, Wang M, Zhang L, Lee EY, et al
    Stage-dependent loss of cortical gyrification as Parkinson disease "unfolds".
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002492.
    PubMed     Text format     Abstract available


  64. GRUNEWALD A, Klein C
    Urinary LRRK2 phosphorylation: Penetrating the thicket of Parkinson disease?
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002438.
    PubMed     Text format    


  65. PAGANO G, Ferrara N, Brooks DJ, Pavese N, et al
    Age at onset and Parkinson disease phenotype.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002461.
    PubMed     Text format     Abstract available


  66. KEMPSTER PA
    Biomarkers for the progression of Parkinson disease.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002473.
    PubMed     Text format    


  67. FRASER KB, Moehle MS, Alcalay RN, West AB, et al
    Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002436.
    PubMed     Text format     Abstract available


  68. ABBOTT RD, Ross GW, Petrovitch H, Masaki KH, et al
    Midlife milk consumption and substantia nigra neuron density at death.
    Neurology. 2016;86:512-9.
    PubMed     Text format     Abstract available


  69. CHEN H, Marder K
    Milk consumption and the risk of nigral degeneration.
    Neurology. 2016;86:496-7.
    PubMed     Text format    


    January 2016
  70. ODEKERKEN VJ, Boel JA, Schmand BA, de Haan RJ, et al
    GPi vs STN deep brain stimulation for Parkinson disease: Three-year follow-up.
    Neurology. 2016 Jan 27. pii: 10.1212/WNL.0000000000002401.
    PubMed     Text format     Abstract available


  71. STOESSL AJ
    Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?
    Neurology. 2016;86:228.
    PubMed     Text format    


  72. GAO X, O'Reilly EJ, Schwarzschild MA, Ascherio A, et al
    Prospective study of plasma urate and risk of Parkinson disease in men and women.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002351.
    PubMed     Text format     Abstract available


  73. RIZZO G, Copetti M, Arcuti S, Martino D, et al
    Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002350.
    PubMed     Text format     Abstract available


  74. KOSCHMIDDER E, Weissbach A, Bruggemann N, Kasten M, et al
    A nonsense mutation in CHCHD2 in a patient with Parkinson disease.
    Neurology. 2016 Jan 13. pii: 10.1212/WNL.0000000000002361.
    PubMed     Text format    


    December 2015
  75. PAYER DE, Guttman M, Kish SJ, Tong J, et al
    D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002285.
    PubMed     Text format     Abstract available


  76. LOHLE M, Mende J, Wolz M, Beuthien-Baumann B, et al
    Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002286.
    PubMed     Text format     Abstract available


  77. TSAI HH, Liou HH, Muo CH, Lee CZ, et al
    Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study.
    Neurology. 2015 Dec 23. pii: 10.1212/WNL.0000000000002307.
    PubMed     Text format     Abstract available


  78. HATANO T, Kurita N, Kobayashi M, Hattori N, et al
    Teaching Video NeuroImages: Re-emergent jaw tremor in Parkinson disease.
    Neurology. 2015;85:e181.
    PubMed     Text format    


    November 2015
  79. LABBE C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, et al
    Role for the microtubule-associated protein tau variant p.A152T in risk of alpha-synucleinopathies.
    Neurology. 2015;85:1680-6.
    PubMed     Text format     Abstract available


  80. WITJAS T, Carron R, Krack P, Eusebio A, et al
    A prospective single-blind study of Gamma Knife thalamotomy for tremor.
    Neurology. 2015;85:1562-8.
    PubMed     Text format     Abstract available


  81. GOLDSTEIN DS, Holmes C, Sharabi Y, Wu T, et al
    Survival in synucleinopathies: A prospective cohort study.
    Neurology. 2015;85:1554-61.
    PubMed     Text format     Abstract available


    October 2015
  82. VENTURA MI, Edwards JD, Barnes DE
    More than just a movement disorder: Why cognitive training is needed in Parkinson disease.
    Neurology. 2015 Oct 30. pii: 10.1212/WNL.0000000000002158.
    PubMed     Text format    


  83. LEUNG IH, Walton CC, Hallock H, Lewis SJ, et al
    Cognitive training in Parkinson disease: A systematic review and meta-analysis.
    Neurology. 2015 Oct 30. pii: 10.1212/WNL.0000000000002145.
    PubMed     Text format     Abstract available


  84. JANELIDZE S, Lindqvist D, Francardo V, Hall S, et al
    Increased CSF biomarkers of angiogenesis in Parkinson disease.
    Neurology. 2015 Oct 28. pii: 10.1212/WNL.0000000000002151.
    PubMed     Text format     Abstract available


  85. MUNOZ DG, Woulfe JM
    Angiogenesis: A new paradigm for Parkinson disease with practical and pathogenic implications.
    Neurology. 2015 Oct 28. pii: 10.1212/WNL.0000000000002160.
    PubMed     Text format    


  86. TINAZZI M, Fasano A, Geroin C, Morgante F, et al
    Pisa syndrome in Parkinson disease: An observational multicenter Italian study.
    Neurology. 2015 Oct 21. pii: 10.1212/WNL.0000000000002122.
    PubMed     Text format     Abstract available


  87. BRONSTEIN JM, Odekerken VJ, Boel JA, Schmand BA, et al
    Neuropsychological outcome after deep brain stimulation for Parkinson disease.
    Neurology. 2015;85:1433-4.
    PubMed     Text format    


  88. ODEKERKEN VJ, Boel JA, Schmand BA, de Bie RM, et al
    Author response.
    Neurology. 2015;85:1433-4.
    PubMed     Text format    


  89. UNGER MM, Sakakibara R
    Does REM sleep behavior disorder have the guts to be Parkinson disease?
    Neurology. 2015 Oct 16. pii: 10.1212/WNL.0000000000002130.
    PubMed     Text format    


  90. HASSAN A, Benarroch EE
    Heterogeneity of the midbrain dopamine system: Implications for Parkinson disease.
    Neurology. 2015 Oct 16. pii: 10.1212/WNL.0000000000002137.
    PubMed     Text format    


  91. IACONO D, Geraci-Erck M, Rabin ML, Adler CH, et al
    Parkinson disease and incidental Lewy body disease: Just a question of time?
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002102.
    PubMed     Text format     Abstract available


  92. VAN DER HOLST HM, van Uden IW, Tuladhar AM, de Laat KF, et al
    Cerebral small vessel disease and incident parkinsonism: The RUN DMC study.
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002082.
    PubMed     Text format     Abstract available


  93. LUCA CC, Rundek T
    Parkinsonism, small vessel disease, and white matter disease: Is there a link?
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002091.
    PubMed     Text format    


    September 2015
  94. PARK JE
    Reflections: Neurology and the Humanities. Not too late.
    Neurology. 2015;85:e88.
    PubMed     Text format    


  95. PIGOTT K, Rick J, Xie SX, Hurtig H, et al
    Longitudinal study of normal cognition in Parkinson disease.
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002001.
    PubMed     Text format     Abstract available


  96. HERSHEY LA, Peavy GM
    Cognitive decline in Parkinson disease: How steep and crowded is the slope?
    Neurology. 2015 Sep 11. pii: 10.1212/WNL.0000000000002003.
    PubMed     Text format    


  97. WANG L, Aasly JO, Annesi G, Bardien S, et al
    Large-scale assessment of polyglutamine repeat expansions in Parkinson disease.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002016.
    PubMed     Text format     Abstract available


  98. ROSSI S, Ulivelli M
    The olfactory side of Parkinson disease: Relevance for clinical practice.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002005.
    PubMed     Text format    


  99. LEE DH, Oh JS, Ham JH, Lee JJ, et al
    Is normosmic Parkinson disease a unique clinical phenotype?
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000001999.
    PubMed     Text format     Abstract available


  100. FILLA A
    CAG repeats in idiopathic Parkinson disease: To screen or not to screen.
    Neurology. 2015 Sep 9. pii: 10.1212/WNL.0000000000002024.
    PubMed     Text format    


  101. MORTIBOYS H, Furmston R, Bronstad G, Aasly J, et al
    UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2(G2019S) carriers and in vivo.
    Neurology. 2015;85:846-52.
    PubMed     Text format     Abstract available


  102. HUOT P, Hutchison WD
    Serotonin/dopamine transporter ratio as a predictor of L-dopa-induced dyskinesia.
    Neurology. 2015;85:840-1.
    PubMed     Text format    


  103. RUFFMANN C, Parkkinen L, Woulfe JM, Gray MT, et al
    Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease.
    Neurology. 2015;85:834-5.
    PubMed     Text format    


  104. VISANJI NP, Lang AE, Hazrai LN
    Author response.
    Neurology. 2015;85:834-5.
    PubMed     Text format    


  105. WOULFE JM, Gray MT, Munoz G
    Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease.
    Neurology. 2015;85:834.
    PubMed     Text format    


    August 2015
  106. OOSTERVELD LP, Allen JC Jr, Ng EY, Seah SH, et al
    Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants.
    Neurology. 2015 Aug 26. pii: 10.1212/WNL.0000000000001953.
    PubMed     Text format     Abstract available


  107. KELLEY JM, Espay AJ, Dwivedi A, Lang AE, et al
    Placebo effect of medication cost in Parkinson disease: A randomized double-blind study.
    Neurology. 2015;85:742-3.
    PubMed     Text format    


  108. KELLEY JM
    Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.
    Neurology. 2015;85:742-3.
    PubMed     Text format    


  109. XIE T, Vigil J, MacCracken E, Warnke P, et al
    Author Response.
    Neurology. 2015;85:557.
    PubMed     Text format    


  110. SIDIROPOULOS C
    Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD.
    Neurology. 2015;85:557.
    PubMed     Text format    


  111. GREENAMYRE JT, Sanders LH, Gasser T
    Fruit flies, bile acids, and Parkinson disease: A mitochondrial connection?
    Neurology. 2015 Aug 7. pii: 10.1212/WNL.0000000000001912.
    PubMed     Text format    


  112. LEE JY, Seo S, Lee JS, Kim HJ, et al
    Putaminal serotonergic innervation: Monitoring dyskinesia risk in Parkinson disease.
    Neurology. 2015 Aug 7. pii: 10.1212/WNL.0000000000001909.
    PubMed     Text format     Abstract available


  113. NIRENBERG MJ
    Preoperative factors of apathy in subthalamic stimulated Parkinson disease: A PET study.
    Neurology. 2015;85:483.
    PubMed     Text format    


  114. WORTHINGTON JM, Ney J
    The end of life with PD can be well-lived: the neurologist's role.
    Neurology. 2015;85:394-5.
    PubMed     Text format    


  115. KOGA S, Aoki N, Uitti RJ, van Gerpen JA, et al
    When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients.
    Neurology. 2015;85:404-12.
    PubMed     Text format     Abstract available


    July 2015
  116. NA YC, Chang WS, Jung HH, Kweon EJ, et al
    Unilateral magnetic resonance-guided focused ultrasound pallidotomy for Parkinson disease.
    Neurology. 2015 Jul 15. pii: 10.1212/WNL.0000000000001826.
    PubMed     Text format    


  117. KIM SJ, Udupa K, Ni Z, Moro E, et al
    Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease.
    Neurology. 2015 Jul 8. pii: 10.1212/WNL.0000000000001806.
    PubMed     Text format     Abstract available


  118. MARDER K, Wang Y, Alcalay RN, Mejia-Santana H, et al
    Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
    Neurology. 2015;85:89-95.
    PubMed     Text format     Abstract available


  119. SAFARPOUR D, Thibault DP, DeSanto CL, Boyd CM, et al
    Nursing home and end-of-life care in Parkinson disease.
    Neurology. 2015 Jul 2. pii: 10.1212/WNL.0000000000001715.
    PubMed     Text format     Abstract available


  120. XIE T, Guan R, Staisch J, Towle VL, et al
    Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS.
    Neurology. 2015 Jul 2. pii: 10.1212/WNL.0000000000001809.
    PubMed     Text format    


    June 2015
  121. THOLFSEN LK, Larsen JP, Schulz J, Tysnes OB, et al
    Development of excessive daytime sleepiness in early Parkinson disease.
    Neurology. 2015 Jun 17. pii: 10.1212/WNL.0000000000001737.
    PubMed     Text format     Abstract available


  122. RACETTE BA, Willis AW
    Time to change the blind men and the elephant approach to Parkinson disease?
    Neurology. 2015 Jun 12. pii: 10.1212/WNL.0000000000001739.
    PubMed     Text format     Abstract available


  123. MULLER ML, Albin RL, Bohnen NI, Jennings D, et al
    Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study.
    Neurology. 2015;84:2292.
    PubMed     Text format    


  124. JENNINGS D, Siderowf A, Stern M, Seibyl J, et al
    Author Response.
    Neurology. 2015;84:2292.
    PubMed     Text format    


    May 2015
  125. GUSTAFSSON H, Nordstrom A, Nordstrom P
    Depression and subsequent risk of Parkinson disease: A nationwide cohort study.
    Neurology. 2015 May 20. pii: 10.1212/WNL.0000000000001684.
    PubMed     Text format     Abstract available


  126. BRIDEL C, Garibotto V
    Teaching NeuroImages: Drug-induced parkinsonism with asymmetrical putaminal DaT binding.
    Neurology. 2015;84:e159.
    PubMed     Text format    


  127. MCKEOWN MJ, Peavy GM
    Biomarkers in Parkinson disease: It's time to combine.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001692.
    PubMed     Text format    


  128. CAMPBELL MC, Koller JM, Snyder AZ, Buddhala C, et al
    CSF proteins and resting-state functional connectivity in Parkinson disease.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001681.
    PubMed     Text format     Abstract available


    April 2015
  129. CARRIERE N, Lopes R, Defebvre L, Delmaire C, et al
    Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease.
    Neurology. 2015 Apr 29. pii: 10.1212/WNL.0000000000001619.
    PubMed     Text format     Abstract available


  130. PICILLO M, Fasano A
    How much does sex matter in Parkinson disease?
    Neurology. 2015 Apr 29. pii: 10.1212/WNL.0000000000001621.
    PubMed     Text format    


  131. LIU R, Umbach DM, Peddada SD, Xu Z, et al
    Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease.
    Neurology. 2015 Apr 29. pii: 10.1212/WNL.0000000000001609.
    PubMed     Text format     Abstract available


  132. GUSTAFSSON H, Aasly J, Strahle S, Nordstrom A, et al
    Low muscle strength in late adolescence and Parkinson disease later in life.
    Neurology. 2015 Apr 3. pii: 10.1212/WNL.0000000000001534.
    PubMed     Text format     Abstract available


  133. WANG C
    Muscle strength at age 18 and Parkinson disease among Swedish men from a nationwide cohort.
    Neurology. 2015 Apr 3. pii: 10.1212/WNL.0000000000001549.
    PubMed     Text format    


    March 2015
  134. TROSTER AI, Massano J
    Changes in cognitive abilities after deep brain stimulation for Parkinson disease.
    Neurology. 2015;84:e98-9.
    PubMed     Text format    


  135. GALDUROZ JC, Ramos AC, Santos-Galduroz RF, Liang JW, et al
    Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study.
    Neurology. 2015;84:1386-7.
    PubMed     Text format    


  136. WEINTRAUB D, Papay K, Xie SX
    Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.
    Neurology. 2015;84:1386-7.
    PubMed     Text format    


  137. LIANG JW, Shanker VL, Groves M
    Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study.
    Neurology. 2015;84:1386-7.
    PubMed     Text format    


  138. MASSANO J, Troster AI
    About deep brain stimulation.
    Neurology. 2015;84:e100-1.
    PubMed     Text format    


  139. CALANDRELLA D, Romito LM, Elia AE, Del Sorbo F, et al
    Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease.
    Neurology. 2015 Mar 25. pii: 10.1212/WNL.0000000000001500.
    PubMed     Text format     Abstract available


  140. KAWADA T, Anang JB, Postuma R
    Predictors of dementia in Parkinson disease: A prospective cohort study.
    Neurology. 2015;84:1285-6.
    PubMed     Text format    


  141. ANANG JB, Postuma R
    Author response.
    Neurology. 2015;84:1285-6.
    PubMed     Text format    


    February 2015
  142. ODEKERKEN VJ, Boel JA, Geurtsen GJ, Schmand BA, et al
    Neuropsychological outcome after deep brain stimulation for Parkinson disease.
    Neurology. 2015 Feb 27. pii: 10.1212/WNL.0000000000001419.
    PubMed     Text format     Abstract available


  143. MASSANO J
    New insights on cognition after deep brain stimulation in Parkinson disease.
    Neurology. 2015 Feb 27. pii: 10.1212/WNL.0000000000001432.
    PubMed     Text format    


  144. LEWITT PA, Kim S
    The pharmacodynamics of placebo: expectation effects of price as a proxy for efficacy.
    Neurology. 2015;84:766-7.
    PubMed     Text format    


  145. SERAFIN A, Foco L, Zanigni S, Blankenburg H, et al
    Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD.
    Neurology. 2015;84:645-53.
    PubMed     Text format     Abstract available


  146. POSTUMA RB, Gagnon JF, Bertrand JA, Genier Marchand D, et al
    Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials.
    Neurology. 2015 Feb 13. pii: 10.1212/WNL.0000000000001364.
    PubMed     Text format     Abstract available


  147. KENBORG L, Rugbjerg K, Lee PC, Ravnskjaer L, et al
    Head injury and risk for Parkinson disease: Results from a Danish case-control study.
    Neurology. 2015 Feb 13. pii: 10.1212/WNL.0000000000001362.
    PubMed     Text format     Abstract available


  148. BEECHAM GW, Dickson DW, Scott WK, Martin ER, et al
    PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease.
    Neurology. 2015 Feb 6. pii: 10.1212/WNL.0000000000001332.
    PubMed     Text format     Abstract available


  149. SIMON-SANCHEZ J, Gasser T
    Parkinson disease GWAS: The question of lumping or splitting is back again.
    Neurology. 2015 Feb 6. pii: 10.1212/WNL.0000000000001345.
    PubMed     Text format    


  150. HU Y, Yu SY, Zuo LJ, Cao CJ, et al
    Parkinson disease with REM sleep behavior disorder: Features, alpha-synuclein, and inflammation.
    Neurology. 2015 Feb 6. pii: 10.1212/WNL.0000000000001308.
    PubMed     Text format     Abstract available


  151. GAN-OR Z, Amshalom I, Kilarski LL, Bar-Shira A, et al
    Differential effects of severe vs mild GBA mutations on Parkinson disease.
    Neurology. 2015 Feb 4. pii: 10.1212/WNL.0000000000001315.
    PubMed     Text format     Abstract available


  152. SCHOLZ SW, Jeon BS
    GBA mutations and Parkinson disease: When genotype meets phenotype.
    Neurology. 2015 Feb 4. pii: 10.1212/WNL.0000000000001321.
    PubMed     Text format    


  153. MACKAY CE, Szewczyk-Krolikowski K, Ben-Shlomo Y, Hu M, et al
    Author response.
    Neurology. 2015;84:546.
    PubMed     Text format    


  154. MONTGOMERY EB JR
    Functional connectivity in the basal ganglia network differentiates PD patients from controls.
    Neurology. 2015;84:546.
    PubMed     Text format    


    January 2015
  155. ESPAY AJ, Norris MM, Eliassen JC, Dwivedi A, et al
    Placebo effect of medication cost in Parkinson disease: A randomized double-blind study.
    Neurology. 2015 Jan 28. pii: 10.1212/WNL.0000000000001282.
    PubMed     Text format     Abstract available


  156. HELMICH RC, Thaler A, van Nuenen BF, Gurevich T, et al
    Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.
    Neurology. 2015;84:399-406.
    PubMed     Text format     Abstract available


  157. XIE T, Vigil J, MacCracken E, Gasparaitis A, et al
    Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD.
    Neurology. 2015;84:415-20.
    PubMed     Text format     Abstract available


  158. MARZ M, Ferracin M, Klein C
    MicroRNAs as biomarker of Parkinson disease? Small but mighty.
    Neurology. 2015 Jan 16. pii: 10.1212/WNL.0000000000001275.
    PubMed     Text format    


  159. VISANJI NP, Marras C, Kern DS, Al Dakheel A, et al
    Colonic mucosal alpha-synuclein lacks specificity as a biomarker for Parkinson disease.
    Neurology. 2015 Jan 14. pii: 10.1212/WNL.0000000000001240.
    PubMed     Text format     Abstract available


  160. STURM W, Fuhr P, Zimmermann R, Gschwandtner U, et al
    Cognitive training in Parkinson disease: Cognition-specific vs nonspecific computer training.
    Neurology. 2015;84:104-5.
    PubMed     Text format    


  161. FUHR P, Zimmermann R, Gschwandtner U
    Author response.
    Neurology. 2015;84:104-5.
    PubMed     Text format    


    December 2014
  162. CANNING CG, Sherrington C, Lord SR, Close JC, et al
    Exercise for falls prevention in Parkinson disease: A randomized controlled trial.
    Neurology. 2014 Dec 31. pii: 10.1212/WNL.0000000000001155.
    PubMed     Text format     Abstract available


    November 2014
  163. KARCESKI S
    New ways to assess brain function in Parkinson disease.
    Neurology. 2014;83:e199-201.
    PubMed     Text format    


  164. HALL S, Surova Y, Ohrfelt A, Zetterberg H, et al
    CSF biomarkers and clinical progression of Parkinson disease.
    Neurology. 2014 Nov 19. pii: 10.1212/WNL.0000000000001098.
    PubMed     Text format     Abstract available



  165. Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease.
    Neurology. 2014;83:1880.
    PubMed     Text format    


  166. BURKE WJ, Bronstein JM, Fitzmaurice A
    Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease.
    Neurology. 2014;83:1879-80.
    PubMed     Text format    


  167. BRONSTEIN JM, Fitzmaurice A
    Author response.
    Neurology. 2014;83:1879-80.
    PubMed     Text format    


  168. ROSSI M, Merello M
    Teaching NeuroImages: Pisa syndrome in Parkinson disease.
    Neurology. 2014;83:e177.
    PubMed     Text format    


    October 2014
  169. PENA J, Ibarretxe-Bilbao N, Garcia-Gorostiaga I, Gomez-Beldarrain MA, et al
    Improving functional disability and cognition in Parkinson disease: Randomized controlled trial.
    Neurology. 2014 Oct 31. pii: 10.1212/WNL.0000000000001043.
    PubMed     Text format     Abstract available


  170. FLODEN D, Cooper SE, Griffith SD, Machado AG, et al
    Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation.
    Neurology. 2014;83:1627-33.
    PubMed     Text format     Abstract available


  171. DONADIO V
    Author response.
    Neurology. 2014;83:1582.
    PubMed     Text format    


    September 2014
  172. CILIA R, Reale C, Castagna A, Nasca A, et al
    Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia.
    Neurology. 2014;83:1155-62.
    PubMed     Text format     Abstract available


  173. CONTARINO MF, Bour LJ, Verhagen R, Lourens MA, et al
    Directional steering: A novel approach to deep brain stimulation.
    Neurology. 2014;83:1163-9.
    PubMed     Text format     Abstract available


  174. ORY-MAGNE F, Rascol O
    Author response.
    Neurology. 2014;83:1036.
    PubMed     Text format    


  175. POSSNER A
    Reflections: neurology and the humanities: acceptance speech for my father.
    Neurology. 2014;83:1032.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: